Congress moves to void ACA marketplace rules for 2027, risking coverage chaos
H.J.Res. 197 — Providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Patient Protection and Affordable Care Act, HHS Notice of Benefit and Payment Parameters for 2027; and Basic Health Program". · Filed by Kathy Castor (D-FL) · 16 cosponsors · Introduced Jun 18, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This is a Congressional Review Act resolution that disapproves a Centers for Medicare & Medicaid Services rule setting health insurance benefit and payment parameters for 2027 under the Affordable Care Act. If passed, the rule would be nullified and have no legal effect, potentially disrupting ACA marketplace operations and Basic Health Program coverage for 2027.
Why we flagged it
This is a Congressional Review Act disapproval resolution targeting a routine regulatory rule. CRA resolutions are procedural instruments designed to nullify agency rules; this one targets ACA marketplace operations. The mechanism is straightforward—disapprove the rule, void it—but the effect is deregulatory: removing the 2027 benefit and payment framework that governs ACA marketplace function.
What the text implies
- Disapproving the rule does not automatically restore a prior rule; it creates a regulatory vacuum for 2027 ACA marketplace operations, forcing CMS to either issue a new rule or operate without current guidance, potentially triggering legal challenges and marketplace instability.
- The resolution targets a routine annual rule-setting process; if successful, it establishes a precedent for using CRA to block annual ACA regulatory updates, which could become a recurring tactic to destabilize the marketplace.
The full analysis lists 4 implications of this text.
Who stands to gain
health insurance carriers (reduced regulatory compliance burden, potential for higher premiums due t; pharmacy benefit managers and medical device manufacturers (potential for reduced coverage mandates